Phenotype standardization for statin-induced myotoxicity

A. Alfirevic; D. Neely; J. Armitage; H. Chinoy; R. G. Cooper; R. Laaksonen; D. F. Carr; K. M. Bloch; J. Fahy; A. Hanson; Q. Y. Yue; M. Wadelius; A. H. Maitland-van Der Zee; D. Voora; B. M. Psaty; C. N. A. Palmer; M. Pirmohamed

doi:10.1038/clpt.2014.121

Phenotype standardization for statin-induced myotoxicity

A. Alfirevic (Lead / Corresponding author), D. Neely, J. Armitage, H. Chinoy, R. G. Cooper, R. Laaksonen, D. F. Carr, K. M. Bloch, J. Fahy, A. Hanson, Q. Y. Yue, M. Wadelius, A. H. Maitland-van Der Zee, D. Voora, B. M. Psaty, C. N. A. Palmer, M. Pirmohamed

Research output: Contribution to journal › Article › peer-review

148 Citations (Scopus)

188 Downloads (Pure)

Abstract

Statins are widely used lipid-lowering drugs that are effective in reducing cardiovascular disease risk. Although they are generally well tolerated, they can cause muscle toxicity, which can lead to severe rhabdomyolysis. Research in this area has been hampered to some extent by the lack of standardized nomenclature and phenotypic definitions. We have used numerical and descriptive classifications and developed an algorithm to define statin-related myotoxicity phenotypes, including myalgia, myopathy, rhabdomyolysis, and necrotizing autoimmune myopathy.

Original language	English
Pages (from-to)	470-476
Number of pages	7
Journal	Clinical Pharmacology & Therapeutics
Volume	96
Issue number	4
Early online date	4 Jun 2014
DOIs	https://doi.org/10.1038/clpt.2014.121
Publication status	Published - Oct 2014

ASJC Scopus subject areas

Pharmacology (medical)
Pharmacology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/clpt.2014.121

Publisher final version
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material.
Final published version, 311 KBLicence: CC BY-NC-ND

Cite this

Alfirevic, A., Neely, D., Armitage, J., Chinoy, H., Cooper, R. G., Laaksonen, R., Carr, D. F., Bloch, K. M., Fahy, J., Hanson, A., Yue, Q. Y., Wadelius, M., Maitland-van Der Zee, A. H., Voora, D., Psaty, B. M., Palmer, C. N. A., & Pirmohamed, M. (2014). Phenotype standardization for statin-induced myotoxicity. Clinical Pharmacology & Therapeutics, 96(4), 470-476. https://doi.org/10.1038/clpt.2014.121

@article{790220404f7342de9f710b5021ac68e8,

title = "Phenotype standardization for statin-induced myotoxicity",

abstract = "Statins are widely used lipid-lowering drugs that are effective in reducing cardiovascular disease risk. Although they are generally well tolerated, they can cause muscle toxicity, which can lead to severe rhabdomyolysis. Research in this area has been hampered to some extent by the lack of standardized nomenclature and phenotypic definitions. We have used numerical and descriptive classifications and developed an algorithm to define statin-related myotoxicity phenotypes, including myalgia, myopathy, rhabdomyolysis, and necrotizing autoimmune myopathy.",

author = "A. Alfirevic and D. Neely and J. Armitage and H. Chinoy and Cooper, {R. G.} and R. Laaksonen and Carr, {D. F.} and Bloch, {K. M.} and J. Fahy and A. Hanson and Yue, {Q. Y.} and M. Wadelius and {Maitland-van Der Zee}, {A. H.} and D. Voora and Psaty, {B. M.} and Palmer, {C. N. A.} and M. Pirmohamed",

year = "2014",

month = oct,

doi = "10.1038/clpt.2014.121",

language = "English",

volume = "96",

pages = "470--476",

journal = "Clinical Pharmacology & Therapeutics",

issn = "0009-9236",

publisher = "American Society for Clinical Pharmacology and Therapeutics",

number = "4",

}

Alfirevic, A, Neely, D, Armitage, J, Chinoy, H, Cooper, RG, Laaksonen, R, Carr, DF, Bloch, KM, Fahy, J, Hanson, A, Yue, QY, Wadelius, M, Maitland-van Der Zee, AH, Voora, D, Psaty, BM, Palmer, CNA & Pirmohamed, M 2014, 'Phenotype standardization for statin-induced myotoxicity', Clinical Pharmacology & Therapeutics, vol. 96, no. 4, pp. 470-476. https://doi.org/10.1038/clpt.2014.121

TY - JOUR

T1 - Phenotype standardization for statin-induced myotoxicity

AU - Alfirevic, A.

AU - Neely, D.

AU - Armitage, J.

AU - Chinoy, H.

AU - Cooper, R. G.

AU - Laaksonen, R.

AU - Carr, D. F.

AU - Bloch, K. M.

AU - Fahy, J.

AU - Hanson, A.

AU - Yue, Q. Y.

AU - Wadelius, M.

AU - Maitland-van Der Zee, A. H.

AU - Voora, D.

AU - Psaty, B. M.

AU - Palmer, C. N. A.

AU - Pirmohamed, M.

PY - 2014/10

Y1 - 2014/10

N2 - Statins are widely used lipid-lowering drugs that are effective in reducing cardiovascular disease risk. Although they are generally well tolerated, they can cause muscle toxicity, which can lead to severe rhabdomyolysis. Research in this area has been hampered to some extent by the lack of standardized nomenclature and phenotypic definitions. We have used numerical and descriptive classifications and developed an algorithm to define statin-related myotoxicity phenotypes, including myalgia, myopathy, rhabdomyolysis, and necrotizing autoimmune myopathy.

AB - Statins are widely used lipid-lowering drugs that are effective in reducing cardiovascular disease risk. Although they are generally well tolerated, they can cause muscle toxicity, which can lead to severe rhabdomyolysis. Research in this area has been hampered to some extent by the lack of standardized nomenclature and phenotypic definitions. We have used numerical and descriptive classifications and developed an algorithm to define statin-related myotoxicity phenotypes, including myalgia, myopathy, rhabdomyolysis, and necrotizing autoimmune myopathy.

UR - http://www.scopus.com/inward/record.url?scp=84903401941&partnerID=8YFLogxK

U2 - 10.1038/clpt.2014.121

DO - 10.1038/clpt.2014.121

M3 - Article

C2 - 24897241

SN - 0009-9236

VL - 96

SP - 470

EP - 476

JO - Clinical Pharmacology & Therapeutics

JF - Clinical Pharmacology & Therapeutics

IS - 4

ER -

Phenotype standardization for statin-induced myotoxicity

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

PREDICTION-ADR: Personalisation of tREatment In Cardiovascular Disease Through Next Generation Sequencing - Adverse Drug Reactions (Joint with University of Uppsala, University of Liverpool and University of Utrecht)

Palmer, Colin

Cite this

Phenotype standardization for statin-induced myotoxicity

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Projects

PREDICTION-ADR: Personalisation of tREatment In Cardiovascular Disease Through Next Generation Sequencing - Adverse Drug Reactions (Joint with University of Uppsala, University of Liverpool and University of Utrecht)

Profiles

Palmer, Colin

Cite this